Fig. 6.

Effect of GMCI and anti–PD-1 on immune checkpoint receptors in treated tumor bearing animals. (A) PD-1+ CD8+ T cells as a percentage of live CD45+CD3+ cells, and (B)TIM-3+ cells as a percentage of live CD45+CD3+ cells. (C) PD-1+/TIM-3+ T effector cells as a percentage of live CD45+CD3+CD8+ cells. (D) Representative images of CD8+/CTLA-4+ effector T cells as a percentage of live CD45+CD3+ cells for untreated, anti–PD-1, GMCI, and GMCI/anti–PD-1 combination. (D) Quantification of CD8+/CTLA-4+ effector T cells as a percentage of live CD45+CD3+CD8+ cells. Graphs include values for individually analyzed mice and the mean ± SD per treatment group. Long horizontal bars indicate the mean values. Shorter horizontal bars indicate the standard deviation. One-way ANOVA was used to determine statistical significance (***P ≤ 0.0001, ***P ≤ 0.001, **P ≤ 0.01, *P ≤ 0.05).